ELVN.US Enliven Therapeutics Inc.

Healthcare Pharmaceuticals USA Stocks
48.80 USD
Close of Nov 13, 2026
14.79 62.32
Market cap
USD 3.59B
P/E
-
P/B
4.05x
ROE
-12.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ELVN.US undervalued?

Graham number

The Graham number of Enliven Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Enliven Therapeutics Inc. fundamental analysis

No fundamental analysis for Enliven Therapeutics Inc. yet.

Enliven Therapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Enliven Therapeutics Inc.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical…

Full company profile